Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
COX-1 and glycoprotein receptor polymorphisms are linked to antiplatelet effect of aspirin
April 21st, 2006
Polymorphisms of COX-1 and GPVI are associated with the antiplatelet effect of aspirin in coronary artery disease patients. "The antiplatelet effect of aspirin varies individually. This study evaluated whether the antiplatelet effect of aspirin associates with polymorphisms in the genes coding for cyclo-oxygenase-1 (COX-1) and several platelet glycoprotein (GP) receptors in patients with stable coronary artery disease (CAD)," investigators in Finland report. A. Lepantalo and colleagues working with the University of Helsinki explained, "Blood samples were collected from 101 aspirin-treated (mean 100 mg/d) patients. Compliance to treatment was...
Source: Science Letter (2006-04-21)
|
